Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortiumChijioke Nze, Narendranath Epperla, Allison M. Bock et al.|Blood|2025Cited by 0
Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomasAndrew Jallouk, Sairah Ahmed, Lorenzo Falchi et al.|Blood|2025Cited by 0
Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamabAllison M. Bock, Sairah Ahmed, Alex F. Herrera et al.|Blood|2025Cited by 0
Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world studyDavid Qualls, Sairah Ahmed, Andrew Jallouk et al.|Blood|2025Cited by 0
Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium StudyKunhwa Kim, Ajay Major, Zhouxuan Li et al.|Blood|2025Cited by 0